Manuel Quintana-Díaz1,2, Raúl Muñoz-Romo3, Susana Gómez-Ramírez4, José Pavía5, Alberto M Borobia2,3, José A García-Erce2,6, Manuel Muñoz7. 1. Intensive Care Unit, University Hospital La Paz, Madrid, Spain. 2. Research Institute, University Hospital La Paz (IdiPAZ), Madrid, Spain. 3. Clinical Pharmacology, School of Medicine, Autonomous University of Madrid, Madrid, Spain. 4. Internal Medicine, University Hospital Virgen de la Victoria, Málaga, Spain. 5. Pharmacology, School of Medicine, University of Málaga, Málaga, Spain. 6. Haematology and Haemotherapy, Research Institute of Aragón, General Hospital San Jorge, Huesca, Spain. 7. Transfusion Medicine, School of Medicine, University of Málaga, Málaga, Spain.
Abstract
BACKGROUND: A fast-track anaemia clinic (FTAC) for the management of moderate-to-severe iron-deficiency anaemia (IDA) was established in our Emergency Department in 2010. In this FTAC, the replacement of packed red cell transfusion by ferric carboxymaltose administration was proven to be safe and effective. The aim of this study was a cost-analysis of IDA management in the FTAC, comparing this management with the previous standard care pathway consisting of packed red cell transfusion, if needed, and referral to outpatient specialised care. MATERIALS AND METHODS: A cost study was performed for patients with IDA who were at risk of requiring transfusion (haemoglobin <9 g/dL) but did not require hospitalisation. Total IDA treatment costs in the FTAC were compared to those theoretically incurred if these patients had been managed using the standard care pathway. In addition, a sensitivity analysis considering variations of up to ±30% in ferric carboxymaltose and packed red cell acquisition costs was performed (49 possible scenarios). RESULTS: Between 2012 and 2015, 238 IDA patients were treated in the FTAC. The average treatment cost was € 594±337/patient in the FTAC group and € 672±301/patient in the standard care pathway group, with a saving of € 78±28/patient (95% CI, 22-133; p<0.001). The sensitivity analysis showed that IDA treatment costs in the FTAC (€ 480-722/patient), compared with those of the standard care pathway (€ 550-794/patient), resulted in significant cost-savings for all studied scenarios (€ 51-104/patient; p<0.005). DISCUSSION: The administration of ferric carboxymaltose for IDA management in a FTAC may be cost-saving compared with the standard care pathway.
BACKGROUND: A fast-track anaemia clinic (FTAC) for the management of moderate-to-severe iron-deficiency anaemia (IDA) was established in our Emergency Department in 2010. In this FTAC, the replacement of packed red cell transfusion by ferric carboxymaltose administration was proven to be safe and effective. The aim of this study was a cost-analysis of IDA management in the FTAC, comparing this management with the previous standard care pathway consisting of packed red cell transfusion, if needed, and referral to outpatient specialised care. MATERIALS AND METHODS: A cost study was performed for patients with IDA who were at risk of requiring transfusion (haemoglobin <9 g/dL) but did not require hospitalisation. Total IDA treatment costs in the FTAC were compared to those theoretically incurred if these patients had been managed using the standard care pathway. In addition, a sensitivity analysis considering variations of up to ±30% in ferric carboxymaltose and packed red cell acquisition costs was performed (49 possible scenarios). RESULTS: Between 2012 and 2015, 238 IDA patients were treated in the FTAC. The average treatment cost was € 594±337/patient in the FTAC group and € 672±301/patient in the standard care pathway group, with a saving of € 78±28/patient (95% CI, 22-133; p<0.001). The sensitivity analysis showed that IDA treatment costs in the FTAC (€ 480-722/patient), compared with those of the standard care pathway (€ 550-794/patient), resulted in significant cost-savings for all studied scenarios (€ 51-104/patient; p<0.005). DISCUSSION: The administration of ferric carboxymaltose for IDA management in a FTAC may be cost-saving compared with the standard care pathway.
Authors: Xavier Bosch; Frank Palacios; Gabriel Inclán-Iríbar; Marta Castañeda; Anna Jordán; Pedro Moreno; Antonio Coca; Alfonso López-Soto Journal: Eur J Intern Med Date: 2011-03-12 Impact factor: 4.487
Authors: Aryeh Shander; Axel Hofmann; Sherri Ozawa; Oliver M Theusinger; Hans Gombotz; Donat R Spahn Journal: Transfusion Date: 2009-12-09 Impact factor: 3.157
Authors: Michael Auerbach; John Adamson; Andreas Bircher; Christian Breymann; Steven Fishbane; Anat Gafter-Gvili; Christoph Gasche; Jeffrey Gilreath; Giuliano Grazzini; David Henry; Giancarlo Liumbruno; Francesco Locatelli; Iain Macdougall; Manuel Munoz; David Rampton; George Rodgers; Aryeh Shander Journal: Haematologica Date: 2015-05 Impact factor: 9.941
Authors: Dante A Suffredini; Wanying Xu; Junfeng Sun; Jesús Barea-Mendoza; Steven B Solomon; Samuel L Brashears; Andreas Perlegas; Daniel B Kim-Shapiro; Harvey G Klein; Charles Natanson; Irene Cortés-Puch Journal: Transfusion Date: 2017-06-27 Impact factor: 3.157
Authors: Manuel Muñoz; Susana Gómez-Ramírez; Martin Besser; José Pavía; Fernando Gomollón; Giancarlo M Liumbruno; Sunil Bhandari; Mercé Cladellas; Aryeh Shander; Michael Auerbach Journal: Blood Transfus Date: 2017-09 Impact factor: 3.443